First investment for Colorcon Ventures in AI drug discovery leader
![](/46/pdcnewsitem/08/44/15/technology-3402365_1920%20(1).jpg)
Atomwise technology removes the barriers of physical screening that have limited the success of traditional methods for small molecule drug discovery.
Colorcon Ventures, a $50 million corporate venture fund of Colorcon Inc., has invested in Atomwise, a provider of artificial intelligence (AI) solutions for drug discovery and inventor of the first deep learning AI technology for structure-based drug design.
The company’s technology, called AtomNet, removes the barriers of physical screening that have limited the success of traditional methods for small molecule drug discovery. Today, AtomNet screens libraries of more than 16 billion molecules against novel biological targets in less than 2 days.
R&D productivity is, according to Martti Hedman, CEO at Colorcon, a "major pain point" for the pharmaceutical industry. To help ease this, Atomwise uses AI for small molecule drug discovery, enabling significant time and cost savings for customers around the world.
With the new investment, Atomwise will continue to scale its AI technology platform — the largest AI-driven drug discovery portfolio in history — and team.
“Over the past 3 years, our platform AtomNet has tackled — and succeeded — in finding small molecule hits for more undruggable targets than any other AI drug discovery platform,” said Abraham Heifets, Atomwise’s co-founder and CEO.
Colorcon Venture's support will also help Atomwise expand $5 billion+ deal pipeline for small molecule drug discovery.
The company also plans to expand its work with corporate partners, which currently include major players in the biopharma space such as Eli Lilly, Bayer, Hansoh Pharmaceuticals, and Bridge Biotherapeutics, as well as emerging biotechnology companies including StemoniX and SEngine Precision Medicine.
![Colorcon](https://www.cphi-online.com/ahdODTdzGmHUP55-comp248219.jpg)
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance